Epizyme Inc. (NASDAQ:EPZM)’s share price reached a new 52-week low on Thursday . The stock traded as low as $8.05 and last traded at $8.19, with a volume of 549,814 shares trading hands. The stock had previously closed at $8.69.

Several research firms have weighed in on EPZM. Leerink Swann restated an “outperform” rating and set a $39.00 target price on shares of Epizyme in a report on Tuesday, June 21st. Zacks Investment Research upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a report on Wednesday. JMP Securities reiterated a “buy” rating and set a $28.00 price target on shares of Epizyme in a report on Thursday, June 23rd. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Epizyme in a report on Monday, May 9th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $26.00 price target on shares of Epizyme in a report on Monday, June 20th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Epizyme currently has an average rating of “Buy” and an average target price of $23.11.

The company’s market cap is $473.69 million. The stock has a 50 day moving average of $10.01 and a 200-day moving average of $10.47.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.03. Equities analysts anticipate that Epizyme Inc. will post ($2.19) EPS for the current fiscal year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $10.37, for a total value of $41,480.00. Following the completion of the sale, the insider now directly owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

An institutional investor recently bought a new position in Epizyme stock. California Public Employees Retirement System purchased a new position in shares of Epizyme Inc. (NASDAQ:EPZM) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,723,000. California Public Employees Retirement System owned 0.41% of Epizyme at the end of the most recent reporting period.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.